MOLECULAR SCREENING IN ADVANCED NON-SMALL CELL LUNG CANCER: A SYSTEMATIC REVIEW OF COST-EFFECTIVENESS ANALYSES FOR FIRST-LINE THERAPY

被引：0
|
作者：
Zaim, Remziye [1 ]
Thunnissen, Erik [2 ]
Dingemans, Anne-Marie [3 ]
Postmus, Pieter E. [2 ]
Uyl-De Groot, Carin A. [1 ]
机构：
[1] Erasmus Univ, NL-3000 DR Rotterdam, Netherlands
[2] Vrije Univ Amsterdam, Med Ctr, Amsterdam, Netherlands
[3] Maastricht Univ, Med Ctr, Maastricht, Netherlands
来源：
JOURNAL OF THORACIC ONCOLOGY | 2013年 / 8卷
关键词：
advanced non-small cell lung cancer; molecular screening; cost-effective; systematic review;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.11-023
引用
收藏
页码：S604 / S605
页数：2
相关论文
共 50 条
  • [1] Cost-Effectiveness of Pembrolizumab as First-Line Therapy for Advanced Non-Small Cell Lung Cancer
    Georgieva, M.
    Aguiar, P., Jr.
    Lima, J. P.
    Haaland, B.
    Lopes, G.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2148 - S2149
  • [2] COST-EFFECTIVENESS OF FIRST-LINE THERAPY FOR ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Yang, M. C.
    Tan, E. C. H.
    [J]. VALUE IN HEALTH, 2014, 17 (07) : A736 - A736
  • [3] Cost-effectiveness of pembrolizumab as first-line therapy for advanced non-small cell lung cancer
    Georgieva, Mina
    da Silveira Nogueira Lima, Joao P.
    Aguiar, Pedro
    Lopes, Gilberto de Lima, Jr.
    Haaland, Benjamin
    [J]. LUNG CANCER, 2018, 124 : 248 - 254
  • [4] Cost-effectiveness of first-line immunotherapies for advanced non-small cell lung cancer
    Yang, Szu-Chun
    Ou, Huang-Tz
    Su, Wu-Chou
    Wang, Shi-Yi
    [J]. CANCER MEDICINE, 2023, 12 (07): : 8838 - 8850
  • [5] Cost-Effectiveness of Pemetrexed as First-Line Maintenance Therapy for Advanced Nonsquamous Non-small Cell Lung Cancer
    Klein, Robert
    Wielage, Ron
    Muehlenbein, Catherine
    Liepa, Astra M.
    Babineaux, Steve
    Lawson, Anthony
    Schwartzberg, Lee
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (08) : 1263 - 1272
  • [6] Cost-Effectiveness of Pemetrexed Plus Cisplatin as First-Line Therapy for Advanced Nonsquamous Non-small Cell Lung Cancer
    Klein, Robert
    Muehlenbein, Catherine
    Liepa, Astra M.
    Babineaux, Steve
    Wielage, Ron
    Schwartzberg, Lee
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (11) : 1404 - 1414
  • [7] Cost-effectiveness of nivolumab plus ipilimumab versus chemotherapy as first-line therapy in advanced non-small cell lung cancer
    Shu, Yamin
    Ding, Yiling
    Li, Feie
    Zhang, Qilin
    [J]. INTERNATIONAL IMMUNOPHARMACOLOGY, 2023, 114
  • [8] The cost-effectiveness of cemiplimab plus chemotherapy as the first-line treatment for advanced non-small cell lung cancer
    Lu, Tingting
    Huang, Yufan
    Cai, Zhongjie
    Lin, Wangchun
    Chen, Xiaoxiao
    Chen, Ruijia
    Hu, Yingying
    [J]. FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [9] Cost-effectiveness analyses of targeted therapy and immunotherapy for advanced non-small cell lung cancer in the United States: a systematic review
    Yu, Anthony
    Huang, Eva
    Abe, Momoka
    An, Kang
    Park, Sun-Kyeong
    Park, Chanhyun
    [J]. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2021, 21 (03) : 381 - 393
  • [10] COST-EFFECTIVENESS ANALYSIS OF TREMELIMUMAB AS FIRST-LINE THERAPY FOR METASTATIC NON-SMALL CELL LUNG CANCER IN JAPAN
    Sakai, R.
    Moriwaki, K.
    Morimoto, K.
    Shimozuma, K.
    [J]. VALUE IN HEALTH, 2024, 27 (06) : S150 - S150
12345